JANÍKOVÁ, Andrea, Karol BOLČÁK, Tomáš PAVLÍK, Jiří MAYER and Zdeněk KRÁL. Value of [F-18]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: The end of a dilemma? CLINICAL LYMPHOMA & MYELOMA. 2008, vol. 8, No 5, p. 287-293. ISSN 1557-9190.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Value of [F-18]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: The end of a dilemma?
Name in Czech Význam FDG PET v léčbě folikulárního lymfomu. Konec dilematu?
Name (in English) Value of [F-18]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: The end of a dilemma?
Authors JANÍKOVÁ, Andrea (203 Czech Republic, guarantor), Karol BOLČÁK (203 Czech Republic), Tomáš PAVLÍK (203 Czech Republic), Jiří MAYER (203 Czech Republic) and Zdeněk KRÁL (203 Czech Republic).
Edition CLINICAL LYMPHOMA & MYELOMA, 2008, 1557-9190.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 1.596
RIV identification code RIV/00216224:14110/08:00034559
Organization unit Faculty of Medicine
UT WoS 000260006700004
Keywords (in Czech) nehodgkinský lymfom; přesná diagnostika; F-18-FDG; klasifikace; PET; transplantace
Keywords in English NON-HODGKINS-LYMPHOMA; DIAGNOSTIC-ACCURACY; RESPONSE CRITERIA; WHOLE-BODY; PET; TRANSPLANTATION; CLASSIFICATION; F-18-FDG; INDOLENT; THERAPY
Tags CLASSIFICATION, DIAGNOSTIC-ACCURACY, F-18-FDG, INDOLENT, NON-HODGKINS-LYMPHOMA, PET, RESPONSE CRITERIA, THERAPY, TRANSPLANTATION, WHOLE-BODY
Tags Reviewed
Changed by Changed by: RNDr. Tomáš Pavlík, Ph.D., učo 52483. Changed: 1/4/2010 09:24.
Abstract
[F-18]Fluorodeoxyglucose (FDG) positron emission tomography (PET) is a powerful tool for the imaging of various lymphomas. Despite its high FDG avidity, there is little data on PET in follicular lymphoma (FL). In this work, we present findings concerning PET at staging and posttreatment evaluation in FL. Patients and Methods: A total of 181 PET scans were evaluated in 117 patients with FL in a retrospective study. Positron emission tomography-based results were compared with conventional staging in 82 patients. Posttreatment PET evaluation was performed in 99 patients; there were comparable progression-free survivals of PET-positive and PET-negative patients. Results: Positron emission tomography showed more involvement than computed tomography (CT) with clinical examination in 41 of 82 patients (50%), less in 11 of 82 (13%); the same extension was found in 27 of 82 patients (33%), and 3 patients revealed discordant foci visible on PET only and lymphadenopathy without PET activity (P < .001). Including the results of trephine biopsy, PET finally upstaged FL in 15 of 82 patients (18%), which was projected in change of treatment strategy. There were 73 of 99 negative posttreatment PET scans; 54 of 73 PET-negative patients (74%) remain in complete remission (median follow-up, 27 months); 19 (26%) of them relapsed with median of 12 months. Fourteen of 20 (70%) PET-positive patients relapsed with a median of 4.5 months regardless of findings on CT and subsequent therapy. The difference in relapse rates between PET-positive and PET-negative patients is statistically significant (P < .001). Conclusion: Positron emission tomography at staging is able to substantially change treatment strategy in an important proportion of patients with FL. Persisting PET positivity after treatment predicts for a high risk of an early relapse and can identify patients with poor prognosis.
Abstract (in English)
[F-18]Fluorodeoxyglucose (FDG) positron emission tomography (PET) is a powerful tool for the imaging of various lymphomas. Despite its high FDG avidity, there is little data on PET in follicular lymphoma (FL). In this work, we present findings concerning PET at staging and posttreatment evaluation in FL. Patients and Methods: A total of 181 PET scans were evaluated in 117 patients with FL in a retrospective study. Positron emission tomography-based results were compared with conventional staging in 82 patients. Posttreatment PET evaluation was performed in 99 patients; there were comparable progression-free survivals of PET-positive and PET-negative patients. Results: Positron emission tomography showed more involvement than computed tomography (CT) with clinical examination in 41 of 82 patients (50%), less in 11 of 82 (13%); the same extension was found in 27 of 82 patients (33%), and 3 patients revealed discordant foci visible on PET only and lymphadenopathy without PET activity (P < .001). Including the results of trephine biopsy, PET finally upstaged FL in 15 of 82 patients (18%), which was projected in change of treatment strategy. There were 73 of 99 negative posttreatment PET scans; 54 of 73 PET-negative patients (74%) remain in complete remission (median follow-up, 27 months); 19 (26%) of them relapsed with median of 12 months. Fourteen of 20 (70%) PET-positive patients relapsed with a median of 4.5 months regardless of findings on CT and subsequent therapy. The difference in relapse rates between PET-positive and PET-negative patients is statistically significant (P < .001). Conclusion: Positron emission tomography at staging is able to substantially change treatment strategy in an important proportion of patients with FL. Persisting PET positivity after treatment predicts for a high risk of an early relapse and can identify patients with poor prognosis.
Links
MSM0021622430, plan (intention)Name: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie
Investor: Ministry of Education, Youth and Sports of the CR, Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies
PrintDisplayed: 25/4/2024 09:24